Sirolimus-Eluting Stent vs. Intravascular Brachytherapy in In-Stent Restenotic Coronary Artery Lesions(SISR)
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
The main objective of this study is to demonstrate the superiority or non-inferiority of the sirolimus-eluting Bx VELOCITY® stent compared to intravascular brachytherapy in patients with in-stent restenotic native coronary artery lesions.
| Condition | Intervention | Phase |
|---|---|---|
|
In-Stent Restenosis |
Device: Sirolimus-Eluting Bx Velocity® Balloon Expandable Stent Procedure: Brachytherapy |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Multicenter, Randomized Study of the Sirolimus-Eluting Bx VELOCITY® BALLOON Expandable Stent vs. Intravascular Brachytherapy in the Treatment of Patients With In-Stent Restenotic Coronary Artery Lesions |
- Target vessel failure (TVF) defined as cardiac death, myocardial infarction, or target vessel revascularization at 9 months post-procedure. [ Time Frame: 9 months post-procedure. ] [ Designated as safety issue: Yes ]
- Angiographic in-lesion and in-stent binary restenosis (³ 50% diameter stenosis) at 6 months post-procedure (by QCA). [ Time Frame: 6 months post-procedure ] [ Designated as safety issue: Yes ]
- Post-procedure and six-month in-stent and in-lesion percent diameter stenosis (%DS) and late loss at 6 months post-procedure (by QCA) - [analysis at 6 months chosen so that results from the GAMMA Trial can be used]. [ Time Frame: 6 months post-procedure ] [ Designated as safety issue: Yes ]
- Post-procedure and six-month in-stent and in-lesion minimum lumen diameter (MLD) (by QCA). [ Time Frame: Post-procedure and at six-month ] [ Designated as safety issue: Yes ]
- Target lesion revascularization (TLR) at 6 and 9 months post-procedure. [ Time Frame: 6 and 9 months post-procedure ] [ Designated as safety issue: Yes ]
- Target vessel revascularization (TVR) at 6 and 9 months post-procedure. [ Time Frame: 6 and 9 months post-procedure ] [ Designated as safety issue: Yes ]
- Composite of Major Adverse Cardiac Events (MACE) defined as death, myocardial infarction (Q wave and non-Q wave), emergent bypass surgery, or repeat target lesion revascularization at 30 days and 6, 9, and 12-months, and 2, 3, 4, and 5 years post-proce [ Time Frame: 30 days and 6, 9, and 12-months, and 2, 3, 4, and 5 years post-procedure ] [ Designated as safety issue: Yes ]
- Stent lumen and stent obstruction volume by intravascular ultrasound (IVUS) at post-procedure and six months in a subset of patients conducted at 5-7 investigational centers. [ Time Frame: post-procedure and six months ] [ Designated as safety issue: Yes ]
- Cost associated with the index hospitalization, length of stay, and repeat hospitalizations during the 12 mo post-procedure follow-up. [ Time Frame: 12 mo post-procedure ] [ Designated as safety issue: No ]
- Rate of late thrombosis [ Time Frame: Throughout study ] [ Designated as safety issue: Yes ]
| Enrollment: | 384 |
| Study Start Date: | February 2003 |
| Study Completion Date: | September 2009 |
| Primary Completion Date: | January 2005 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 1
Cypher Bx Velocity
|
Device: Sirolimus-Eluting Bx Velocity® Balloon Expandable Stent
Sirolimus-Eluting Bx Velocity® Balloon Expandable Stent
|
|
Active Comparator: 2
Brachytherapy
|
Procedure: Brachytherapy
Brachytherapy
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
1. The patient has an in-stent restenosis of > 50% (by subjective angiographic determination of the minimal luminal diameter compared to the distal reference diameter) within a native coronary artery which has previously undergone stent placement ( 4 weeks). Lesions must meet ISR Classification I-III.
2. The patient has a history, signs of, or laboratory studies that suggest coronary ischemia attributable to the target stenosis. The diagnosis of angina pectoris is defined by Canadian Cardiovascular Society Classification (CCS I, II, III, or IV) OR unstable angina pectoris (Braunwald Classification B&C, I-II) OR patients with documented silent ischemia;
3. The study target lesion must be located in an in-stent restenotic native coronary artery measuring > 2.75mm and 3.5mm in diameter and > 15mm and 40mm in length to allow treatment with a maximum of three 18mm stents. The target lesion must have undergone coronary interventional treatment > 4 weeks previously. Patients with one or more prior percutaneous coronary interventions at the target lesion are acceptable candidates.
4. The vessel 1cm distal to the target lesion is > 2.5mm in diameter;
5. Ejection Fraction must be > 40%;
6. The study target lesion cannot be located in a vessel containing a second lesion requiring treatment at the time of the procedure.
7. Male or non-pregnant female patients > 18 years of age inclusive. NOTE: Females of child-bearing potential must have a negative pregnancy test (urine or serum) prior to enrollment and must use birth control for 6 months.
Exclusion Criteria:
- The study target lesion has definite or possible thrombus present by angiographic criteria.
- The patient has experienced a Q-wave or non-Q-wave myocardial infarction with documented total CK > 2 times normal within the preceding 24 hours and the CK and CK-MB enzymes remain above normal at the time of treatment.
- Impaired renal function (Serum creatinine > 2.0mg/dl);
- The patient has unstable angina classified as Braunwald III B or C, or is having peri infarction angina.
- The left ventricular ejection fraction is < 40%.
- The target vessel has previously sustained a perforation.
- Totally occluded vessel (TIMI 0 level);
- Prior stent within 5mm of target lesion;
- There is a total occlusion of the restenosed-stent (ISR Classification IV) prior to the interventional procedure.
- Has an ostial target lesion;
- Significant (> 50%) in-stent restenoses proximal or distal to the target lesion that might require revascularization or impede runoff;
Contacts and Locations| United States, Minnesota | |
| Mayo Clinic Rochester | |
| Rochester, Minnesota, United States, 55905 | |
| Principal Investigator: | David R. Holmes, Jr., MD | Mayo Clinic Rochester, Minnesota |
More Information
Publications:
| Responsible Party: | David R. Holmes, Jr., MD, Mayo Clinic Rochester, Minnesota |
| ClinicalTrials.gov Identifier: | NCT00231257 History of Changes |
| Other Study ID Numbers: | P02-6313 |
| Study First Received: | September 30, 2005 |
| Last Updated: | November 17, 2009 |
| Health Authority: | United States: Food and Drug Administration |
Additional relevant MeSH terms:
|
Sirolimus Everolimus Antibiotics, Antineoplastic Antineoplastic Agents Therapeutic Uses Pharmacologic Actions |
Antifungal Agents Anti-Infective Agents Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Anti-Bacterial Agents |
ClinicalTrials.gov processed this record on May 22, 2013